{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:42:41Z","timestamp":1790030561142,"version":"4.0.1"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0604-2","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T15:04:30Z","timestamp":1556895870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment"],"prefix":"10.1136","volume":"7","author":[{"given":"Hamzah","family":"Abu-Sbeih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Nguyen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip S.","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoop S.","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Alasadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5148-6130","authenticated-orcid":false,"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"key":"604_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of fda-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339.","journal-title":"Int Immunopharmacol"},{"key":"604_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"604_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tang T, Lu Y, et al. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019;7:31.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"604_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/ibd\/izy104","volume":"24","author":"Yinghong Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24(8):1695\u2013705.","journal-title":"Inflammatory Bowel Diseases"},{"issue":"12","key":"604_CR5","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","volume":"24","author":"Yinghong Wang","year":"2018","unstructured":"Wang Y, Wiesnoski D, Helmink B, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804\u20138.","journal-title":"Nature Medicine"},{"issue":"2","key":"604_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ibd\/izy240","volume":"25","author":"Kati Choi","year":"2018","unstructured":"Choi K, Abu-Sbeih H, Samdani R, et al. Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis. 2019;25(2):385\u201393.","journal-title":"Inflammatory Bowel Diseases"},{"key":"604_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W, et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6:95.","journal-title":"J Immunother Cancer"},{"key":"604_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","volume":"6","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at md Anderson. J Immunother Cancer. 2018;6:37.","journal-title":"J Immunother Cancer"},{"key":"604_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6:142.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"604_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","volume":"68","author":"Hamzah Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Qiao W, et al. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother. 2019;68(4):553\u201361.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"604_CR11","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/j.jtho.2017.10.007","volume":"13","author":"JH Cho","year":"2018","unstructured":"Cho JH, Sun JM, Lee SH, et al. Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer. J Thorac Oncol. 2018;13:e34\u2013e6.","journal-title":"J Thorac Oncol"},{"key":"604_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-017-2062-3","volume":"67","author":"J Kashima","year":"2018","unstructured":"Kashima J, Okuma Y, Shimizuguchi R, et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018;67:61\u20135.","journal-title":"Cancer Immunol Immunother"},{"key":"604_CR13","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368.","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"604_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","volume":"16","author":"JA Thompson","year":"2018","unstructured":"Thompson JA. New nccn guidelines: recognition and management of immunotherapy-related toxicity. J Natl Compr Cancer Netw. 2018;16:594\u20136.","journal-title":"J Natl Compr Cancer Netw"},{"key":"604_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (sitc) toxicity management working group. J Immunother Cancer. 2017;5:95.","journal-title":"J Immunother Cancer"},{"key":"604_CR16","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119\u2013iv42.","journal-title":"Ann Oncol"},{"key":"604_CR17","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The american joint committee on cancer: the 7th edition of the ajcc cancer staging manual and the future of tnm. Ann Surg Oncol. 2010;17:1471\u20134.","journal-title":"Ann Surg Oncol"},{"key":"604_CR18","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00464-013-3344-2","volume":"28","author":"TT Jayakrishnan","year":"2014","unstructured":"Jayakrishnan TT, Groeschl RT, George B, et al. Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. Surg Endosc. 2014;28:1505\u201314.","journal-title":"Surg Endosc"},{"key":"604_CR19","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1002\/cncr.23961","volume":"113","author":"RW Thomsen","year":"2008","unstructured":"Thomsen RW, Thomsen HF, Norgaard M, et al. Risk of cholecystitis in patients with cancer: a population-based cohort study in Denmark. Cancer. 2008;113:3410\u20139.","journal-title":"Cancer"},{"key":"604_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.leukres.2005.08.029","volume":"30","author":"M Gorschluter","year":"2006","unstructured":"Gorschluter M, Mey U, Strehl J, et al. Cholecystitis in neutropenic patients: retrospective study and systematic review. Leuk Res. 2006;30:521\u20138.","journal-title":"Leuk Res"},{"key":"604_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3816\/CGC.2009.n.011","volume":"7","author":"G Gomez-Abuin","year":"2009","unstructured":"Gomez-Abuin G, Karam AA, Mezzadri NA, et al. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer. 2009;7:62\u20133.","journal-title":"Clin Genitourin Cancer"},{"key":"604_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1752-1947-6-69","volume":"6","author":"K Nakano","year":"2012","unstructured":"Nakano K, Suzuki K, Morita T. Life-threatening acute acalculous cholecystitis in a patient with renal cell carcinoma treated by sunitinib: a case report. J Med Case Rep. 2012;6:69.","journal-title":"J Med Case Rep"},{"key":"604_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1177\/1078155210363317","volume":"17","author":"B Cetin","year":"2011","unstructured":"Cetin B, Coskun U, Yildiz R, et al. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus. J Oncol Pharm Pract. 2011;17:274\u20138.","journal-title":"J Oncol Pharm Pract"},{"key":"604_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investig New Drugs. 2017;35:529\u201336.","journal-title":"Investig New Drugs"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0604-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0604-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0604-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:44:14Z","timestamp":1601055854000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0604-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0604-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"22 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics approval of this study was granted by the Institutional Review Board committee at The University of Texas MD Anderson Cancer Center (PA18\u20130472). Consent was waived for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study was granted a waiver for consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"118"}}